logo
‘I'm 26 and slowly dying. In 10 days I'll find out if the NHS can give me a life-saving wonder drug'

‘I'm 26 and slowly dying. In 10 days I'll find out if the NHS can give me a life-saving wonder drug'

Telegraph5 days ago
Early last year, 26-year-old Caitlin Monachan received a devastating diagnosis. She has Niemann-Pick disease, an ultra-rare genetic disorder caused by a missing enzyme, where toxic material builds up in the body, fatally damaging the lungs, liver and spleen. There is no cure – but there is a wonder drug that considerably extends life, not by years but by decades. In adults the drug Xenpozyme could mean 30 more years of healthy life. For a child with early access, it could mean normal life expectancy.
Xenpozyme is saving patients' lives in 22 countries around the world. But not Monachan's. The drug has been rejected for approval for use on the NHS, and in a little over a week's time the window for renegotiation closes for good. For Monachan and other patients like her, that is tantamount to a death sentence.
'It's gut-wrenching, it's heartbreaking, that I don't get the treatment just because I live in the UK,' Monachan tells me when I visit her in Belfast. 'There is one other person in Northern Ireland [with Niemann-Pick disease] who has the treatment on compassionate grounds. Why does she get it and not me? If I want a fulfilling life, I need it. It can get your symptoms back to normal. I just want to be normal.'
Monachan's doctor had applied for compassionate use, where patients with serious or life-threatening conditions are given drugs not yet approved for general use when no other suitable treatment options are available, but the request was denied.
Monachan is the loser in a cruel drug lottery. Soon after her diagnosis, the National Institute for Health and Care Excellence (NICE) announced it would not approve Xenpozyme for use on the NHS as it is too expensive. Despite lobbying from NPUK, the only UK charity dedicated to the condition, the NHS, NICE and Sanofi – the pharmaceutical company that developed the drug – have shown no flexibility on price, meaning that negotiations are at a stalemate. Toni Mathieson, the chief executive of NPUK, explains: 'NICE have indicated that there is still a window for negotiation… but the deadline is 10 days away on August 1. If nothing changes, the window to secure access will then close indefinitely.'
That's why NPUK is desperately trying to change the tides on this devastating decision, led by Mathieson, who herself has lost three children to the disease. Earlier this month, Mathieson attended the All-Party Parliamentary Group on rare, genetic and undiagnosed conditions in Parliament. Her mission was to lobby MPs to signal to Sanofi that the NHS is willing to go back to the negotiating table. The charity has urged people to write to their local MP, to Wes Streeting, the Health Secretary, and to Paul Hudson, Sanofi's chief executive. With the final deadline fast approaching, Monachan and her family are losing hope.
We are speaking at the kitchen table in Monachan's flat-share, while her mother, Moya, joins on the phone from Germany. Despite living in different countries, it's clear they are close. 'When she got her diagnosis, I said, 'You were Caitlin yesterday, and the only difference is you're Caitlin today with an answer, which is always a good thing,'' Moya says. 'We had the encouragement of knowing that there was a treatment that's curative.' Finding out that it wasn't available for Monachan, however, was like a 'gut punch'.
For as long as she can remember, Monachan has suffered a range of debilitating and seemingly random symptoms. Growing up in southern England, she had persistent migraines, fatigue and insomnia, and broke so many bones she was jokingly nicknamed 'Calamity Caitlin' by her family. She bled excessively from minor injuries. 'I bleed a lot because I don't tend to clot,' she says. 'So I'm on my period for 20 days of the month, which is hard.' She is small, but so is her mother, so her parents didn't think anything of it. An optician once noticed that she had a cherry-red spot on her retina – another telltale sign of Niemann-Pick – but it is so rare that no one connected the signs.
It was when the family moved to Munich for her father Andrew's job in the automotive industry, in 2014, and got private health insurance that a doctor discovered other unusual symptoms during a routine medical examination: high cholesterol and an enlarged spleen. Monachan was prescribed statins, and after finishing school, moved to Belfast to be near extended family while she completed a college course in professional cookery. A part-time job at a restaurant chain followed, but Monachan continued to struggle with overwhelming fatigue and bone pain. 'When I come home from work, I have to soak my feet in the bath for an hour because my bones get so sore,' she says. She cannot socialise like other people her age, or work full time.
The reason for this remained a medical mystery until she was referred to Dr Paul Hamilton, a consultant chemical pathologist in Belfast who runs a specialist clinic for lipid disorders. 'He asked, 'Have you ever heard of Niemann-Pick disease?'' Monachan says. 'I was just like, no. And he explained that it's a disease that affects the fat breakdown in your body because you don't have a particular enzyme.'
'Looking at Caitlin now, you'd think she was fine,' Moya says of her daughter. 'But that's how she is now, that's not her future. Caitlin has no guarantee of life expectancy. There's no guarantee she will stay this way – the build-up in her organs will impact her life more and more.'
Xenpozyme stops this build-up in its tracks by replacing the enzyme – acid sphingomyelinase – that is deficient in patients with Niemann-Pick disease. The drug has been in development since the late 1990s, and in such a small community of patients – around 36 people in the UK have Monachan's subtype of the condition – many of that number were actively involved with clinical trials in some way. It is so rare, in fact, that every sufferer in the UK – or their parents or caregivers – can gather for an annual conference run by NPUK. Monachan attended in April this year. 'I got to meet so many other people with the same condition,' she says. 'Unfortunately for me, most of them are actually on treatment on compassionate grounds. That was really frustrating to hear.' There is no guarantee, however, that their treatment can continue.
To say that the medicine is expensive is something of an understatement. NPUK estimates that giving 36 patients access to Xenpozyme would cost the NHS £20m a year – about 0.01 per cent of the total NHS budget. The charity says it does not know the cost per patient, but NICE guidelines for the condition state that the medication costs £3,612 per 20mg vial, excluding VAT. It is administered through fortnightly infusions at a recommended dose of 3mg for each kilogram of body weight, so, based on these figures, each treatment would cost nearly £38,000 for a person who weighed 70kg. However, for such a small group of patients, the charity still believes the drug could be affordable if Sanofi, the French pharmaceutical company that produces it, and the NHS could be persuaded to go back to the table.
'We aren't allowed to be involved in the negotiation on cost, but based on the information that we have, we believe that it will cost £20 million a year,' says Mathieson. She describes this as a 'small amount to save people's lives'. She adds, 'I really feel there is no point in developing a drug if the people who it's meant for can't access it. Surely there has to be an answer or an arrangement that can be reached?'
Mathieson's eldest daughter, Lucy, was diagnosed with a severe form of Niemann-Pick at five weeks old. 'She didn't meet any milestones. She never walked. By the age of two, she could crawl a little bit, but by the age of two and a half, she'd lost all of those skills. And from then, we were on a bit of a slippery slope to the end, really.' In that time, devastatingly, Mathieson and her husband had two more children who died shortly after birth from Niemann-Pick. Lucy defied doctors' predictions of her life expectancy and survived for two more years, but died aged four.
'As a mum, the only thing that brought me hope was the hope of a treatment or a therapy that was just around the corner,' Mathieson says. 'Of course, our patients and families have lived with that hope – and now they're being left with no choice but 'best supportive care', which means visiting hospitals a lot and experiencing increasingly challenging symptoms that are progressive and severe and will lead to an early death.'
When contacted, a NICE spokesman said: 'We were disappointed not to be able to recommend olipudase alfa [the medical name for Xenpozyme], and we realise the decision was disappointing for people with Niemann-Pick disease and those who care for them. Unfortunately, both the company's and the independent external advisory group's cost-effectiveness estimates compared with standard care were over £300,000 per quality-adjusted life-year gained.
'So even when taking into account the substantial effect of olipudase alfa on quality and length of life, the cost-effectiveness estimates are higher than what NICE usually considers an acceptable use of NHS resources for highly specialised technologies.'
Francesca Buzer, an Essex-based mother of two boys, has seen the difference the drug can make first hand. Her son Dexter was just one when he became ill. 'As a baby, he was completely fine, and then when he was about one, I started to notice that he had a really bloated belly,' she says. 'I thought he had some kind of food allergy.' When his stomach got so large he was struggling to eat, Buzer took him to the doctors.
'That August, when he was about one and a half, I had him seen, and they said he had an absolutely giant liver and had to go straight to hospital.' Dexter's liver and spleen were so big they stretched from his chest to his groin. 'I thought he would die,' Buzer says. 'It was a very traumatic, scary time.' The local hospital didn't know what was wrong, so they were transferred to King's College Hospital in London to see a liver specialist, and then to Evelina London Children's Hospital.
'They told us that he had Niemann-Pick disease, that it's extremely rare, and that at that point there was nothing available to help him,' Buzer says. 'Everything fell apart. However, there was a drug that's compassionate-use only, and they would have to put a case together for Dexter and wait for that. He was accepted in March 2023, and it changed his life overnight.'
Within three months, he had bounced back to being like any other boisterous, energetic four-year-old. He was able to attend pre-school for the first time (before the medication, he wasn't allowed to go because of the risk of infection). 'He's such a friendly little laddie, very cheeky and confident. It's been amazing,' Buzer says. 'I don't know what else to say – it's been completely life-changing.'
Dexter's access to the treatment is secured despite NICE's decision not to approve it for us on the NHS. But that has done nothing to assuage Buzer's worries about it being stopped in the future. 'That's scary – really, really scary,' she says. 'There's always a what if. What if it stops? They could stop it at any point if they don't want to pay out for it anymore.' That's what it boils down to, for her, for Monachan, and for everyone affected by this cruel disease: the value of their life being calculated in monetary value. It's now the final countdown. Will they be saved?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Parents, beware the devastating consequences of measles
Parents, beware the devastating consequences of measles

The Guardian

timean hour ago

  • The Guardian

Parents, beware the devastating consequences of measles

After reading the letters about vaccine misinformation and hesitancy (Measles surge shows why vaccinations are crucial, 20 July), I felt I must write to tell you of one unrecognised cause of the drop in vaccine uptake: when I worked as a community school nursing sister in the 1980s, with 11 state schools and a number of private schools that took up the vaccine service, we had 98% uptake of vaccines in the school setting. This was due to the system of sending letters home to parents requesting their consent and following up by phone, if necessary, by the school office staff. The children came in class batches. Then the local health authority decided that this service should be discontinued and parents were invited to take their child to the local GP surgery for their vaccinations. The uptake plummeted to less than 40% of eligible children due to children not taking the letters home, or parents forgetting or losing the letter – or being unable to take time off to take their child to the surgery. When I asked the GPs at the local health centre what the uptake for the cohort of eligible children was, they looked at their records and were surprised, but reluctant to do anything about it. Health visitors were responsible for, and very successful in, advising new mothers when vaccines were due, where to get them and encouraging uptake. It should be compulsory for all vaccines for preschool children (which includes measles) to be done before a child is admitted to school, as in many other countries. As a midwife, I saw a baby born to a mother who had contact with rubella in early pregnancy. The little girl was born with a body rash, had bilateral cataracts and was totally deaf. She was was very ill. Schools for deaf children may return again for these children if vaccination is not taken up for whatever reason. How StephensLiphook, Hampshire I contracted measles just before the NHS was established. With it came serious ear infections, burst eardrums, etc. There were no vaccines, just ear drops. Over the years the infections and operations continued and now, aged 82, I have no hearing with complications. I beg people to think seriously about vaccination. The consequences of measles can sometimes be devastating. Jean JacksonSeer Green, Buckinghamshire I caught measles aged six in 1953, at a time when parents hoped their children would get it (and chicken pox and mumps) so as to gain immunity. My dad, aged 54, had not had measles as a boy, caught it from me and nearly died. The risk of not vaccinating children is not just to WallLondon

'I thought my snoring was from blocked nose, but it was something far worse'
'I thought my snoring was from blocked nose, but it was something far worse'

Daily Mirror

timean hour ago

  • Daily Mirror

'I thought my snoring was from blocked nose, but it was something far worse'

Cornwall mum-of-two Claire Barbery was left in shock after what she thought was a blocked nose and snoring turned out to be something much more serious A mum-of-two was left stunned after what she thought was a harmless blocked nose and new snoring habit turned out to be a sign of a rare and aggressive cancer, which was already eroding her skull. ‌ Claire Barbery, 51, from Newquay, Cornwall, had no idea her mild symptoms were anything to worry about. In fact, she nearly cancelled the very hospital appointment that would change, and possibly save, her life. Claire, who works in a care home, put her persistent nasal blockage down to repeated Covid tests and thought nothing of the fact that she had suddenly started snoring at night. ‌ She said: 'I started snoring, which I'd never done before. I was waking up breathing through my mouth. Even then, I nearly cancelled my hospital appointment. I didn't want to waste anyone's time.' ‌ But in January 2023, after months of no improvement and with her concerns growing, she finally sought help. The mum had olfactory neuroblastoma, a rare cancer that grows in the upper part of the nasal cavity. Scans revealed a 5cm tumour that had already begun eating away at the bone at the base of her skull. Claire was immediately sent for complex and high-risk surgery at Birmingham's Queen Elizabeth Hospital, where consultant surgeon Shahz Ahmed, who specialises in the type of procedure she needed, removed the tumour in a delicate operation that was filmed for Channel 5's gripping documentary Surgeons: A Matter of Life or Death. ‌ He explained: 'This was a very rare form of cancer. It had already gone through the skull base and into the base of the brain. If we hadn't acted, it could have spread through her body. The surgery was high risk – we were working close to the brain's main blood supply, with dangers of stroke, seizures, and even death.' The operation was a success, but not without cost. To ensure all the cancer was removed, surgeons had to take out Claire's olfactory bulbs, meaning she's now permanently lost her sense of smell. After her surgery, Claire underwent six gruelling weeks of chemotherapy and radiotherapy. She's now under close monitoring but is slowly returning to work and spending quality time with her husband Gary and daughters Lowenna, 27, and Keizha, 25. 'I very nearly didn't go to that appointment,' Claire said. 'I thought, 'There's nothing wrong – don't waste NHS time.' But looking back, that decision could've cost me my life.' Now, as part of World Head and Neck Cancer Day, Claire is working with the UK's Get A-Head Charitable Trust to raise awareness and urge others to take persistent symptoms seriously, no matter how small they seem. She said: 'If you know your body, you've got to push. If something feels wrong – don't ignore it.'

Nurses set to reject pay offer as further strike action looms
Nurses set to reject pay offer as further strike action looms

Times

timean hour ago

  • Times

Nurses set to reject pay offer as further strike action looms

Nurses will this week overwhelmingly reject their pay deal, raising the prospect that they will join junior doctors on strike. The Royal College of Nursing (RCN) will warn ministers that they must come back to the table over the summer to avoid a formal strike ballot in the autumn and additional unrest that will further set back NHS recovery. However, public support for doctors' strikes appears to be waning, as ministers accuse them of holding the country to ransom and hospitals report fewer staff joining picket lines. Resident doctors, formerly known junior doctors, are in a five-day walkout after rejecting a 5.4 per cent pay rise, which came after a 22 per cent increase last year. Polling for The Times found that 55 per cent of voters oppose the strike, up from 49 per cent earlier this month, while 32 per cent support it, down four points from the second week of July before the walkouts began. Tom Dolphin, the head of the British Medical Association (BMA), insisted that doctors 'don't want to be on strike', but said the walkouts were necessary because doctors were 'undervalued' and were 'leaving the NHS in large numbers'. He said that pay had to be 'enough to recruit and retain the best doctors'. Ministers have refused to reopen pay talks and negotiations on working conditions collapsed in acrimony last week as ministers accused the BMA of acting in bad faith, while the union said the government had failed to make any concrete offers. • NHS patients told to brace for strikes until Christmas and beyond The BMA is holding out for a full return to 2008 levels of pay and Dolphin said salaries 'reflect the responsibility of these doctors' who were making 'life and death decisions'. He said: 'Even nurses who've had a pretty bad time [are] not as badly off as doctors in terms of lost pay.' Nurses, however, are furious that their 3.6 per cent pay rise this year was lower than doctors' increases for the second year in a row. The RCN is holding an indicative vote on the pay award, which closed on Sunday. The vote is understood to show 'overwhelming' rejection of a deal, with turnout likely to be well over the 50 per cent threshold that would be needed for industrial action. The union is due to announce final results later this week with a call for ministers to return to the table. While the BMA is adamant that headline pay must rise, nurses are thought to be more open to talks on wider pay structures. The RCN has repeatedly complained that nurses can remain on the lowest rung of the NHS pay scale for decades and is expected to press ministers for reforms that would allow them to move up the scale as they gain experience. If no progress is made, a formal strike ballot is likely to be launched in the autumn. A spokesman for the union said: 'The results will be announced to our members later this week. As the largest part of the NHS workforce, nursing staff do not feel valued and the government must urgently begin to turn that around.' It came after ambulance and other hospital staff in the GMB Union voted to reject the 3.6 per cent offer last week, with strike action now being considered. The BMA consultants' committee is also holding an indicative vote over a 4 per cent pay deal it described an 'insult' to senior doctors. Dolphin said the vote was 'a testing of the waters to see where people are', but warned: 'We're certainly very aware already, even before we've done this ballot, the consultants are also very much down on their pay [compared with 2008].' He told Sky News he did not recognise reports that doctors were being paid £6,000 a shift to cover for strikes, but said overtime rates were 'whatever they can manage to negotiate with their employer'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store